Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Saniona AB (publ) (SANION.ST)
Glostrup, DK
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.89% | +7.24% | +2.42% | -22.82% | -18.07% | -31.90% | +74.18% | +123.48% | -19.99% | -46.85% | +202.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+29.8% ★ Q1'26: -52.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+22.2% Q1'26: -306.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+62.2% ★ Q1'26: -1,102.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+63.2% ★ Q1'26: -1,185.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+470.4% ★ Q1'26: -286.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+23.3% Q1'26: +19.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.63M
est: 13.69M (-0.4%)
|
74.92M
est: 90.56M (-17.3%)
|
20.69M
est: 51.71M (-60.0%)
|
54.88M
est: 57.00M (-3.7%)
|
2.66M
est: 13.33M (-80.1%)
|
8.20M
est: 17.00M (-51.8%)
|
10.48M
est: 47.50M (-77.9%)
|
15.28M
est: 13.00M (+17.6%)
|
16.84M
est: 17.00M (-0.9%)
|
334.67M
est: 341.00M (-1.9%)
|
434.40M
est: 19.10M (+2,174.3%)
|
11.00M
11.00M – 11.00M
-42.4% YoY
|
20.80M
20.80M – 20.80M
+89.1% YoY
|
| EBITDA |
-28.50M
est: -8.89M (-220.5%)
|
4.54M
est: -58.82M (+107.7%)
|
-55.71M
est: -33.58M (-65.9%)
|
-53.68M
est: -37.02M (-45.0%)
|
-68.71M
est: -8.66M (-693.5%)
|
-65.07M
est: -11.04M (-489.3%)
|
-398.86M
est: -30.85M (-1,192.9%)
|
-198.41M
est: -8.44M (-2,250.0%)
|
-68.28M
est: -11.04M (-518.5%)
|
251.90M
est: -109.08M (+330.9%)
|
281.45M
est: -6.11M (+4,706.6%)
|
-3.52M
-3.52M – -3.52M
+42.4% YoY
|
-6.65M
-6.65M – -6.65M
-89.1% YoY
|
| EBIT |
-29.21M
est: -8.95M (-226.3%)
|
5.15M
est: -59.23M (+108.7%)
|
-56.28M
est: -33.82M (-66.4%)
|
-48.13M
est: -37.28M (-29.1%)
|
-76.24M
est: -8.72M (-774.3%)
|
-69.87M
est: -11.12M (-528.4%)
|
-407.53M
est: -31.07M (-1,211.8%)
|
-206.23M
est: -8.50M (-2,325.5%)
|
-77.93M
est: -11.12M (-600.9%)
|
239.12M
est: -111.70M (+314.1%)
|
274.72M
est: -6.26M (+4,491.0%)
|
-3.60M
-3.60M – -3.60M
+42.4% YoY
|
-6.81M
-6.81M – -6.81M
-89.1% YoY
|
| Net Income |
-22.95M
est: -146.58M (+84.3%)
|
2.22M
est: 27.93M (-92.1%)
|
-49.19M
est: -78.42M (+37.3%)
|
-41.06M
est: -130.64M (+68.6%)
|
-75.79M
est: -279.53M (+72.9%)
|
-73.43M
est: -250.03M (+70.6%)
|
-410.90M
est: -379.36M (-8.3%)
|
-245.36M
est: -163.36M (-50.2%)
|
-95.81M
|
188.71M
|
284.67M
|
—
— – —
|
—
— – —
|
| SGA |
23.93M
est: 95.30M (-74.9%)
|
51.10M
est: 630.42M (-91.9%)
|
51.39M
est: 359.97M (-85.7%)
|
80.15M
est: 396.78M (-79.8%)
|
74.98M
est: 92.81M (-19.2%)
|
97.11M
est: 118.34M (-17.9%)
|
239.27M
est: 330.65M (-27.6%)
|
1.86M
est: 90.49M (-98.0%)
|
—
est: 118.34M (-100.0%)
|
1.28M
est: 1.57B (-99.9%)
|
—
est: 87.71M (-100.0%)
|
50.51M
50.51M – 50.51M
-42.4% YoY
|
95.52M
95.52M – 95.52M
+89.1% YoY
|
| EPS |
-1.29
est: -1.37 (+5.6%)
|
0.11
est: 0.26 (-57.8%)
|
-2.23
est: -0.73 (-205.0%)
|
-1.84
est: -1.22 (-51.1%)
|
-2.49
est: -2.61 (+4.5%)
|
-1.52
est: -2.33 (+34.8%)
|
-5.57
est: -3.54 (-57.5%)
|
-3.33
est: -1.52 (-118.6%)
|
-1.49
|
1.77
|
2.21
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.04% | 284.5K | 0.24% |
| 2 | Avantis International Small Cap Value ETF AVDV | 0.03% | 6.33M | 0.36% |
| 3 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.01% | 127.6K | 0.39% |
| 4 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 34.2K | 0.30% |
| 5 | Avantis International Equity ETF AVDE | 0.00% | 584.7K | 0.23% |
| 6 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 6.5K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas Feldthus | Co-Founder & Chief Executive Officer | 6M | male |
| Jorgen Drejer | Founder, Deputy Chief Executive Officer & Deputy Chairman of the Board | 321.0K | male |
| Pierandrea Muglia | Chief Medical Officer | 83.0K | — |
| Karin Sandager Nielsen | Chief Scientific Officer | — | female |
| Alex Rodriguez | Head of Toxicology | — | male |
| Stina Westergaard Frederiksen | Head of Clinical Operations | — | — |
| Søren Ebdrup | Head of CMC | — | — |
| Martin Damm Olling | Head of Clinical Development | — | — |
| Janus Schreiber Larsen | Chief Operational Officer | — | male |
| Johnny Stilou | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SANION.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
